AProspective, Open-Label Trial of Galantamine in Autistic Disorder
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Post-mortem studies have reported abnormalities of the cholinergic system in autism. The purpose of this study was to assess the use of galantamine, an acetylcholinesterase inhibitor and nicotinic receptor modulator, in the treatment of interfering behaviors in children with autism. METHODS: Thirteen medication-free children with autism (mean age, 8.8 +/- 3.5 years) participated in a 12-week, open-label trial of galantamine. Patients were rated monthly by parents on the Aberrant Behavior Checklist (ABC) and the Conners' Parent Rating Scale-Revised, and by a physician using the Children's Psychiatric Rating Scale and the Clinical Global Impressions scale. RESULTS: Patients showed a significant reduction in parent-rated irritability and social withdrawal on the ABC as well as significant improvements in emotional lability and inattention on the Conners' Parent Rating Scale--Revised. Similarly, clinician ratings showed reductions in the anger subscale of the Children's Psychiatric Rating Scale. Eight of 13 participants were rated as responders on the basis of their improvement scores on the Clinical Global Impressions scale. Overall, galantamine was well-tolerated, with no significant adverse effects apart from headaches in one patient. CONCLUSION: In this open trial, galantamine was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention. Further controlled trials are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS)
Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02408436 · Cited by 2,432 · cited 9×
“Parent-rated outcome measures included the ABC Brown et al. 2002) Clinician ratings were all completed by the same a Subjects 3 and 12 discontinued galantamine after 5 weeks of treatment due to a worsening of target symptoms; subject 5 discontinued galantamine after 11.5 weeks of treatment due to headaches. physician…”
InfluentialConners, C. K., Sitarenios, G., Parker, J. D. A., & Epstein, J. N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022602400621 · Cited by 1,772
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303 · cited 1×
“Galantamine is an NICOLSON ET AL. hyperactivity subscales of the inhibitor that also acts as an allosteric potentia-tor of nicotinic receptors (Maelicke et al. 2001), a pharmacological profile suggesting a possible role in the treatment of autism.”
Nicotinic receptor abnormalities in the cerebellar cortex in autism
Lee, M. (2002) · Brain · doi:10.1093/brain/awf160 · Cited by 232
Wilens, T. E., Biederman, J., Spencer, T. J., Bostic, J., Prince, J., Monuteaux, M. C., Soriano, J., Fine, C., Abrams, A., Rater, M., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.12.1931 · Cited by 230
Cited by
Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis
Rossignol, D. A., & Frye, R. E. (2012) · Molecular Psychiatry · doi:10.1038/mp.2010.136 · Cited by 907
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
Kas, M. J., Glennon, J. C., Buitelaar, J., Ey, E., Biemans, B., Crawley, J., Ring, R. H., Lajonchere, C., Esclassan, F., Talpos, J., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3268-5 · Cited by 132
Deutsch, S. I., Urbano, M. R., Neumann, S. A., Burket, J. A., & Katz, E. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181d6f7ad · Cited by 99
“Otherwise, galantamine was well tolerated and safe in this sample of children.(34) Although the details about the duration of treatment, doses, and dose titration schedule were not provided, galantamine was reported to have modest, but significant, therapeutic effect in a Bplacebo-controlled, double-blind crossover ra…”
BackgroundMethodInfluentialImmune Dysregulation in Autism Spectrum Disorder
Hsiao, E. Y. (2013) · International Review of Neurobiology · doi:10.1016/b978-0-12-418700-9.00009-5 · Cited by 87
Metadata
- Authors
- Nicolson, R., Craven-Thuss, B., & Smith, J.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2006-10
- Volume
- 16
- Issue
- 5
- Pages
- 621-629
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2045245723
- Cited by
- 89
- References
- 6
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.